Department of Otorhinolaryngology, Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA 19104, USA.
Int Forum Allergy Rhinol. 2013 Mar;3(3):184-7. doi: 10.1002/alr.21140. Epub 2013 Jan 16.
We recently demonstrated the bitter taste receptor T2R38 upregulates sinonasal mucosal innate defense in response to gram-negative quorum-sensing molecules through increased nitric oxide production and mucociliary clearance. T2R38 was initially identified in the quest to understand the variability in bitter taste perception to the compound phenylthiocarbamide (PTC) and demonstrated to have polymorphisms generating diplotypes dividing people into PTC supertasters, heterozygotes (with variable PTC detection), and nontasters. We have further demonstrated that sinonasal epithelial cultures derived from supertasters significantly increase innate defenses in response to gram-negative quorum-sensing molecules compared with sinonasal cultures derived from heterozygotes and nontaster individuals. Based on this data, we hypothesize that supertasters are less likely to require sinus surgery compared with heterozygous or nontasters and that supertasters have improved surgical outcomes.
Banked sinonasal tissue samples from patients who had undergone primary functional endoscopic sinus surgery at the University of Pennsylvania or the Philadelphia Veterans Affairs Medical Center were genotyped for T2R38 and compared to the expected population distribution. Necessity for additional antibiotic therapy following the postoperative healing time frame was evaluated.
A total of 28 patients were included in the study. Only 1 supertaster was identified (expected 5.6, p < 0.043). Additionally, 14 heterozygous and 13 nontaster patients were identified.
This pilot study investigating the genetics of the bitter taste receptor T2R38 in the context of primary sinonasal surgery demonstrates supertaster patients are less likely to need surgical intervention for chronic rhinosinusitis. Additional study is necessary to ascertain postsurgical outcomes.
我们最近发现,苦味受体 T2R38 通过增加一氧化氮的产生和黏液纤毛清除率,上调鼻黏膜固有防御,以响应革兰氏阴性群体感应分子。T2R38 最初是在探索对化合物苯硫脲(PTC)的苦味感知变异性时被发现的,并证明其存在多态性,产生二倍体型,将人群分为 PTC 超味觉者、杂合子(具有可变的 PTC 检测)和非味觉者。我们进一步证明,与来自杂合子和非味觉者的鼻黏膜上皮培养物相比,来自超味觉者的鼻黏膜上皮培养物在响应革兰氏阴性群体感应分子时,显著增加固有防御。基于这些数据,我们假设与杂合子或非味觉者相比,超味觉者不太可能需要鼻窦手术,并且超味觉者具有更好的手术效果。
对在宾夕法尼亚大学或费城退伍军人事务医疗中心接受过原发性功能性内镜鼻窦手术的患者的鼻组织样本进行 T2R38 基因分型,并与预期的人群分布进行比较。评估术后愈合时间框架后是否需要额外的抗生素治疗。
共有 28 例患者纳入研究。仅鉴定出 1 例超味觉者(预期为 5.6 例,p < 0.043)。此外,还鉴定出 14 例杂合子和 13 例非味觉者。
这项研究调查了苦味受体 T2R38 在原发性鼻鼻窦手术中的遗传学,表明超味觉者患者发生慢性鼻-鼻窦炎需要手术干预的可能性较低。需要进一步研究以确定术后结果。